Cite
MLA Citation
MG Albulescu et al.. “SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study.” Annals of the rheumatic diseases, vol. 76, n.d., pp. 867–868. http://access.bl.uk/ark:/81055/vdc_100135155435.0x000062